R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
... 0.12%, is a therapeutic drug for glaucoma and ocular
hypertension and has been marketed in Japan since ... systemic adverse reactions demonstrates steady ocular
pressure-decreasing action by twice-a-day ... realized through its optic nerve protection and ocular
blood flow-increasing mechanism. Concerning ...
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
... in subjective symptoms measured by the ocular
Surface Disease Index (OSDI) and improvement in patients' most bothersome ocular
"The strong clinical results from ... symptoms (OSDI and patient's most bothersome ocular
symptoms), when administered under normal ...
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
... Bepreve 1.5% was effective at reducing ocular
itching for at least 8 hours after dosing, with high statistical significance for improvement in ocular
itching compared to placebo for up to 16 hours ... Besilate Ophthalmic Solution 1.5% Reduces ocular
Itching Following Dosing in the Conjunctival ...
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
... results from a separate six month intravitreal ocular
biodistribution study, shows the presence of ... have shown activity in both animal models of ocular
disease and in human clinical trials. The ... drug development company focusing on cancer, ocular
diseases (macular degeneration, diabetic ...
Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases
... will offer high-volume, high-quality human ocular
tissue for research, study, collaboration, and ... with blinding diseases."
Key to the successful advancement of ocular
tissue research is having the highest quality ...
ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert;
... Patients Experience Significant Improvement in ocular
Surface Disease and Quality of Life
As reported by Dr. Koffler, mean ocular
surface disease index (OSDI) total scores for ... weeks is especially noteworthy, suggesting that ocular
health and quality of life for dry eye sufferers ...
Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
... and symptoms (itching and redness) of persistent ocular
allergic inflammation. A one-week pre-treatment ... of Ora, Inc. "Patients with a history of chronic ocular
background inflammation make up a large segment of the ocular
allergy market, and are also patients that tend ...
Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
... inflammation and pain associated with ocular
surgery. A supplemental New Drug Application ... of N -(4-hydroxyphenyl) Retinamide in ocular
Session Date/Start Time: Sunday May ... portfolio which includes products that address ocular
diseases and conditions including uveitis, ...
Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
... the 9th Scientific Meeting of the
Association for ocular
Pharmacology and Therapeutics (AOPT) held in ... France. Acute toxicological studies
confirmed the ocular
surface toxicity of anti-glaucomatous eye ... stress conditions.
Nova21027 is a topical ocular
BAK-free emulsion of latanoprost relying ...
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
... to evaluate the safety, tolerability, and ocular
pharmacokinetics (PK) of topically applied ... as well as assess the preventive activity on ocular
inflammation resulting from the surgery. ESBA105 ... development of novel treatments for inflammatory ocular
conditions. We are very pleased to advance our ...
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
... group in subjective symptoms as measured by the ocular
Surface Disease Index (OSDI) or patient's worst ... and placebo groups, and there were no serious ocular
or systemic adverse events.
Another ... industry include therapies for inflammation, ocular
pain, glaucoma, allergy, and dry eye. The ...
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
... approval for Bepreve as an eye drop treatment for ocular
itching associated with allergic conjunctivitis. ... reductions in the primary endpoints of ocular
itching. In addition, the results showed ... response and on additional signs or symptoms of ocular
allergy, including improvement in nasal symptoms. ...
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
... the primary efficacy endpoint of absence of ocular
inflammation 15 days following surgery. In ... the secondary efficacy endpoint of elimination of ocular
pain one day post surgery.
When ... ER exhibited strong trends in both the absence of ocular
inflammation and pain but did not meet ...
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
... of inflammation and pain associated with ocular
(Logo: ... of
the leading causes of blindness, uveitis and ocular
herpes," said Barry
Butler, President and CEO of ... gel, available in Europe for
the treatment of ocular
viral infections for more than 10 years.
Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
... of inflammation and pain
associated with ocular
surgery; it was approved by the US Food and ... not contain benzalkonium chloride
(BAK), a common ocular
preservative known to cause corneal toxicity ... trend continued through Day 42.
discomfort and pain is a debilitating symptom of ...
Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
... in 245 patients undergoing unilateral ocular
surgery. In the
first study of 124 patients, ... than placebo in treating postoperative ocular
pain/discomfort as early as Day 3/4."
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
... Company Will Seek Label for the Treatment of ocular
Itching Associated with ... concentrations in 130 patients with a
history of ocular
allergies. Both concentrations demonstrated ... in total nasal symptoms. There were no
adverse events reported in patients dosed with ...
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
... secondary efficacy endpoints of elimination of ocular
and mean reduction of markers of ... of bromfenac
produced a low overall incidence of ocular
"We undertook this trial in ... anti-inflammatory compound for the
treatment of ocular
inflammation and pain. Xibrom, approved in 2005, ...
OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
... Against Acanthamoeba Keratitis, a Serious ocular
Infection- -Provides Additional Evidence That ... vision impairment or blindness. AK, which in its ocular
commonly infects contact lens wearers, ... rights to a proprietary formulation of
NCT for ocular
uses from Pathogenics, Inc. OPKO is currently ...
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
... both the primary
efficacy endpoint of absence of ocular
inflammation 15 days following
surgery and the secondary efficacy endpoint of elimination of ocular
at day one. In addition, compared to placebo, bromfenac produced a lower
overall incidence of ocular
adverse events. William B. Trattler, ...
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
resolve inflammation in the eye following ocular
surgery. "We are very pleased with the data that ... investigator in the trial. "Being able to treat ocular
disease with a more convenient ... to
offer rapid resolution of inflammation after ocular
surgery would represent
a meaningful advance for ...
Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
... Phase 2 Drug Candidate Protects the ocular
Surface Following Exposure to Controlled ... the total cornea-a measure of damage to the ocular
who received vehicle (p < ... the disruption of the
epithelial barrier on the ocular
surface. Alacrity acquired the worldwide
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
... of its pivotal Phase III clinical trial treating metastatic cutaneous and ocular
melanoma to the liver. The participating cancer centers in this trial ... of melphalan to the liver to treat patients with metastatic cutaneous and ocular
melanoma who have unresectable tumors in the liver. The Delcath System is ...
Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
... The current POT-4 formulation is expected to provide sustained therapeutic ocular
levels of the drug for several months following a single injection.
... the approximately 10-15% of AMD patients with complications resulting from ocular
angiogenesis (growth of new blood vessels and bleeding in the back of the ...
Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
... Adjunct Principal Investigator of Delcath's Phase III Trial treating ocular
and cutaneous melanoma metastatic to the liver, and Principal Investigator ... of melphalan to the liver to treat patients with metastatic cutaneous and ocular
melanoma who have unresectable tumors in the liver. The Delcath PHP ...
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
... study, cataracts developed or
worsened in 4% of patients who underwent ocular
examination prior to therapy
with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in
rodents. Perform a baseline ocular
examination prior to administration of
PROMACTA and, during therapy with ...
FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
... study, cataracts developed or worsened in 4% of patients who underwent ocular
examination prior to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular
examination prior to administration of PROMACTA and, during therapy with ...
Encouraging Gene Therapy Results in Genetic Form of Blindness
... "Phase I Trial of Leber Congenital Amaurosis due
to RPE65 Mutations by ocular
Subretinal Injection of Adeno-Associated Virus
Gene Vector: Short-Term ... adverse events, immune reactions, or systemic toxicity.
gene therapy for inherited retinal disease is undergoing
a birth ...
Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
... an important milestone for this compound
intended to treat a devastating ocular
disease that impacts millions of
"New therapies are ... VEGF Trap-Eye for treatment of wet AMD, diabetic eye
diseases, and other ocular
diseases and disorders. Once approved, Bayer
HealthCare will market VEGF ...
Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
... the back of the eye expected to combine ease of
use, sustained release and ocular
safety. Administering this emulsion
through a single injection can offer ... has developed a broad pipeline of 7
innovative products addressing main ocular
conditions as well as orphan
diseases. Most advanced products include ...
Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
... oxide-donating prostaglandin F2-alpha analog, at the Association
Pharmacology and Therapeutics 8th Scientific Meeting.
NicOx and Pfizer ... This collaboration involves several
separate projects focused on major ocular
diseases and encouraging results
have been observed in the most advanced ...
MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
... 2 trials in
both of these important indications, as well as additional ocular
MacuSight intends to complete its collection ... serve as a potentially highly-efficacious therapeutic for a
wide range of ocular
diseases and conditions, including the treatment and
prevention of wet ....
New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
... Spray demonstrated significant improvement in the treatment of nasal
allergy symptoms of perennial allergic rhinitis (PAR) in
patients 12 years ... the efficacy of Veramyst for patients
suffering from both nasal and ocular
symptoms all year long, not just
during spring and fall allergy seasons," ...
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
... plans to file a second IND early next year for the use of
iSONEP(TM) (the ocular
formulation of humanized Sphingomab) for the
treatment of AMD. The company ... of cancer and other diseases. A second product candidate,
iSONEP(TM) (the ocular
formulation of humanized Sphingomab), has
demonstrated superior results in ...
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
... profile of Sphingomab bolsters not only our cancer program, but also
program, because the drug substance is humanized Sphingomab in
both ... of cancer and other diseases. A second product candidate,
iSONEP(TM) (the ocular
formulation of humanized Sphingomab), has
demonstrated superior results in ...
Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye
... products. Thanks to its proprietary technology
platforms Novasorb(R) and Eyeject(R), the company has developed innovative
products addressing main ocular
conditions as well as orphan diseases. Most
advanced products include Vekacia(R), for treatment of vernal
keratoconjunctivitis, Cyclokat(R), for the ...
Cancer Research 'David' Hopes to Slay 'Cancer Goliath'
... pancreas, prostate, ovary, and stomach. In addition, some effectiveness was seen in an instance of lymphoid leukemia, and one of a glioma of the ocular
nerve. These tests preceded his more recent death due to an unfortunate accident.
As a small Foundation hard hit by the untimely death of their ...
Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
... Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular
injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular ...
ExonHit Therapeutics Expands Strategic Collaboration With Allergan
... of a
The scope of the collaboration is expanded to include epitope* discovery
for the development of antibody therapeutics in ocular
unique gene profiling technology can readily be applied to identify disease
specific target proteins, but also pinpoints novel ...
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
... considered in combination with a short period of oral steroid administration.
Auditory (high-frequency hearing loss, decreased hearing) and ocular
(lens opacities, cataracts, elevations in intraocular pressure and retinal disorders) disturbances have been reported with Exjade therapy in less ...